How Much ARA-290 Per Day? Dosing Protocol Explained

A 2019 randomised controlled trial published in Diabetes Care found that ARA-290 administered at 4mg subcutaneous three times weekly for 28 days improved corneal nerve fibre density in patients with diabetic neuropathy. A measurable structural improvement most interventions fail to achieve. The dose wasn't arbitrary: it reflected the threshold where tissue protective protein (TPP) receptor activation occurs without triggering erythropoietic side effects, the distinction that separates ARA-290 from full-length erythropoietin.

Our team has worked with research institutions designing ARA-290 protocols for metabolic, inflammatory, and neuroprotective endpoints. The dosing gap between efficacy and futility is narrower than most peptides. Underdosing yields no measurable endpoint shift, overdosing adds cost without proportional benefit.

How much ARA-290 per day is used in clinical research protocols?

Most controlled human trials use 4mg subcutaneous administered three times weekly (Monday/Wednesday/Friday pattern), translating to approximately 1.7mg average daily dose when normalised across seven days. Preclinical models exploring neuroprotection have demonstrated efficacy at 1–2mg daily continuous dosing, while metabolic dysfunction studies have tested bolus doses up to 8mg administered less frequently. The variation reflects different pharmacokinetic demands: tissue repair benefits from pulsed higher doses, while anti-inflammatory endpoints appear responsive to lower sustained exposure.

The peptide was never intended as a daily-dose compound in the traditional sense. ARA-290 dosing evolved from attempts to isolate erythropoietin's tissue-protective effects without stimulating red blood cell production. The result is a molecule with a shorter half-life (approximately 5–6 hours) than EPO but sufficient receptor occupancy duration to permit intermittent rather than continuous administration.

This article covers the dose ranges used across different research applications, how subcutaneous vs intravenous administration changes effective dosing, what timing patterns maximise receptor activation without desensitisation, and the storage and reconstitution variables that determine whether your calculated ARA-290 per day daily dose actually reaches target tissues at therapeutic concentration.

The Dosing Range Established Across Human Trials

Controlled ARA-290 trials in humans have tested doses from 1mg to 8mg per administration, with the majority clustering around 4mg subcutaneous. The first Phase 2 trial in sarcoidosis-associated small fibre neuropathy (published in The Lancet 2014) used 4mg subcutaneous three times weekly for 28 days. A protocol that became the template for subsequent tissue repair studies. That dose demonstrated statistically significant improvement in intraepidermal nerve fibre density and neuropathic pain scores versus placebo, establishing 4mg as a benchmark.

Lower doses have been explored in metabolic contexts. A 2017 study examining ARA-290's effect on insulin sensitivity in type 2 diabetes tested 2mg intravenous weekly for 12 weeks, finding modest improvements in HOMA-IR (homeostatic model assessment of insulin resistance) but no change in HbA1c. The lower dose and intravenous route reflected an attempt to achieve systemic anti-inflammatory effects without the peripheral tissue concentration peaks that subcutaneous bolus injections produce.

Higher doses appear in preclinical models more than human trials. Rodent studies testing ARA-290 for acute kidney injury have used doses equivalent to 6–8mg in a 70kg human, administered immediately post-injury as a single bolus. Translation to humans remains speculative. No published human trial has exceeded 8mg per dose, and most researchers consider doses above 6mg to be entering a range where cost and injection volume become limiting factors without clear efficacy gains.

Timing matters as much as total dose. The half-life of approximately 5–6 hours means plasma concentration drops to near-baseline within 24 hours of a single injection. Three-times-weekly dosing creates a pattern where TPP receptor activation occurs in pulses rather than continuously. This may be beneficial, as continuous receptor occupancy can lead to downregulation. Preliminary data from ongoing studies suggest that spreading a 12mg weekly total dose across three 4mg injections outperforms a single 12mg dose on nerve fibre density endpoints.

Subcutaneous vs Intravenous Administration — How Route Changes Effective Dose

Subcutaneous injection is the dominant route in ARA-290 research, but pharmacokinetic behaviour differs meaningfully from intravenous. Subcutaneous 4mg produces a slower rise to peak plasma concentration (Tmax around 3–4 hours) but sustains measurable levels longer than IV bolus. Intravenous administration achieves immediate peak concentration but also faster clearance. The area under the curve (AUC) is similar, but tissue exposure patterns diverge.

For tissue repair applications. Diabetic neuropathy, wound healing, corneal nerve regeneration. Subcutaneous appears superior. The slower absorption allows sustained receptor activation in peripheral tissues where the peptide diffuses from subcutaneous depots. IV dosing creates a sharp systemic spike followed by rapid renal clearance, which may benefit acute inflammatory conditions (sepsis models, ischemia-reperfusion injury) but underperforms for chronic degenerative endpoints.

Dose equivalence is not 1:1. Researchers transitioning from subcutaneous to IV protocols typically reduce the dose by 20–30% to account for the elimination of first-pass subcutaneous degradation and more efficient systemic delivery. A 4mg subcutaneous dose might translate to 3mg IV for comparable receptor occupancy, though direct head-to-head comparison data in humans is limited.

Injection site also matters for subcutaneous dosing. Abdominal subcutaneous fat shows the most consistent absorption kinetics. Less variability than thigh or deltoid sites. Most published protocols specify abdominal injection 5cm lateral to the umbilicus, rotated between quadrants to avoid lipohypertrophy. Our experience reviewing protocols suggests that inconsistent injection sites contribute more dosing variability than researchers account for. A 4mg dose absorbed from fibrotic tissue at a repeatedly-used site may deliver significantly less bioavailable peptide than the same dose from virgin subcutaneous space.

Reconstitution Concentration — The Variable That Determines Actual Dose Delivered

ARA-290 arrives as lyophilised powder requiring reconstitution with bacteriostatic water. The concentration you mix determines injection volume, which in turn affects tissue exposure. Most vials contain 5mg or 10mg lyophilised peptide. Reconstituting a 5mg vial with 1ml bacteriostatic water produces 5mg/ml concentration. A 4mg dose requires 0.8ml injection volume. Reconstituting the same 5mg vial with 2ml produces 2.5mg/ml concentration. Now a 4mg dose requires 1.6ml.

Higher concentration (less diluent) means smaller injection volume, which is preferable for subcutaneous absorption. Volumes above 1ml in a single subcutaneous site can cause localised pressure, discomfort, and slower absorption as the bolus disperses. Most researchers aim for 0.5–1ml injection volume maximum, which for a 4mg dose means reconstituting to at least 4mg/ml concentration.

Stability post-reconstitution is concentration-dependent. Higher concentration solutions (5mg/ml or greater) maintain potency longer under refrigeration than dilute solutions. Bacteriostatic water contains 0.9% benzyl alcohol as preservative, which extends sterility to 28 days refrigerated. But peptide degradation is a separate consideration. Our team recommends using reconstituted ARA-290 within 14 days regardless of bacteriostatic water presence, as freeze-thaw cycles and prolonged aqueous exposure degrade the peptide structure even under ideal temperature control.

Mixing errors are common. Adding too much diluent creates a concentration mismatch that either requires larger injection volume (reducing absorption efficiency) or forces redoing the entire vial at financial loss. The most reliable approach: calculate your target dose in mg, determine how many doses the vial should provide, then divide total vial mg by desired number of doses to determine reconstitution volume. A 10mg vial intended for 5× 2mg doses requires 5ml reconstitution (2mg/ml), making each dose exactly 1ml. If you want smaller injection volume, reduce the number of planned doses and increase concentration accordingly.

ARA-290 Per Day Daily Dose: Comparison Across Research Applications

What If: ARA-290 Dosing Scenarios

What If I Miss a Scheduled Dose in a 3× Weekly Protocol?

Administer the missed dose as soon as you remember if fewer than 48 hours have passed since the scheduled injection, then resume your regular Monday/Wednesday/Friday pattern. If more than 48 hours have passed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to compensate. The receptor activation pattern depends on consistent pulsed exposure; bunching doses closer together disrupts the intended pharmacodynamic profile and increases the risk of receptor desensitisation without improving tissue outcomes.

What If I Want to Switch from 3× Weekly to Daily Dosing?

Divide your weekly total dose by seven to calculate the daily equivalent. A standard 12mg weekly protocol (4mg × 3) becomes approximately 1.7mg daily. Whether this produces comparable effects is unclear: no published trial has directly compared intermittent vs daily ARA-290 administration head-to-head. Theoretical considerations suggest daily dosing may cause faster receptor downregulation, while intermittent dosing allows receptor resensitisation between exposures. If exploring daily dosing, monitor for diminishing response over time. If effects plateau or decline after 4–6 weeks, the dosing pattern may require adjustment back to intermittent.

What If I Reconstitute at the Wrong Concentration?

If you added too much bacteriostatic water and created a dilute solution (e.g., 2mg/ml when you intended 5mg/ml), you can still use it. You'll simply need larger injection volume to reach target dose. A 4mg dose from 2mg/ml solution requires 2ml injection, which exceeds the ideal 1ml subcutaneous volume and may reduce absorption efficiency. Splitting the dose into two 1ml injections at separate sites is an option, though this doubles injection frequency. If you added too little diluent and created an overly concentrated solution, you can add additional bacteriostatic water to the vial to dilute it. But once diluted, you cannot re-concentrate without lyophilising again, which is impractical outside a laboratory.

The Unvarnished Truth About ARA-290 Dose-Response

Here's the honest answer: most of the dose variability you see across studies exists because researchers don't actually know the optimal ARA-290 per day daily dose yet. The 4mg three-times-weekly protocol became standard not because it was proven superior to alternatives in head-to-head trials, but because it worked in the first successful human study and subsequent researchers copied it to maintain protocol comparability. Lower doses might work equally well for certain endpoints. We simply don't have the data because running dose-ranging trials is expensive and ARA-290 remains an investigational compound without commercial backing to fund large-scale optimisation studies.

The tissue-protective effects are real. Nerve fibre density improvements in diabetic neuropathy patients are measurable and reproducible. But the therapeutic window appears narrow. Doses below 3mg show inconsistent results, doses above 6mg don't show proportional improvement, and the space between likely contains the true optimal range that hasn't been precisely mapped. If you're designing a protocol, 4mg three times weekly is the safest evidence-based choice. If you're exploring lower-dose anti-inflammatory applications, 1–2mg daily is defensible based on preclinical data but remains experimental in humans.

One more reality: ARA-290 isn't cheap, and dose directly determines cost. A 28-day protocol at 4mg three times weekly requires approximately 48mg total peptide. At current research-grade pricing, that's a significant expense. Which is why some researchers explore lower doses or less frequent administration. The dose you choose is rarely purely a scientific decision; budget constraints shape protocol design more than most published papers acknowledge.

Our dedication to quality extends across our entire product line. Researchers exploring the potential of compounds like ARA-290 can find the same commitment to purity and consistency in our full peptide collection. Whether you're investigating tissue repair pathways or metabolic modulation, access to reliably sequenced, small-batch synthesised peptides matters. Because dosing precision means nothing if the compound itself is degraded before it reaches the vial.

ARA-290 remains one of the most promising tissue-protective peptides in active research, but its optimal dosing remains partially unresolved. The 4mg intermittent protocol works. Proven across multiple trials in distinct patient populations. Whether it represents the ceiling of efficacy or simply the floor of what's been adequately tested is the question that ongoing studies will eventually answer. Until then, protocols should follow the published evidence, with the understanding that refinement is inevitable as the mechanism becomes better understood.